Overview

A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

This Phase IV, randomized, parallel-group study is designed to evaluate the cataractogenic potential of quetiapine fumarate (SEROQUEL) compared with that of a putative non-cataractogenic antipsychotic medication risperidone (RISPERDAL). This study is being conducted to fulfill the SEROQUEL Phase IV commitment regarding evaluation of cataractogenic potential.

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Quetiapine Fumarate
Risperidone